A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Publication of trial rationale/design

Starting at month 24, a publication is written and submitted to a cardiology journal, describing the rationale and design of the clinical trial; a second publication is written and submitted on month 60, describing the results of the trial.

Abstracts presentation at heart failure meetings

Starting at month 12, abstracts on the scope, design and implementation of the clinical trial are submitted for presentation at Heart Failure congresses

Short presentation of study results to general audience

A short oral presentation of the study results is made to general audience through media communication at the ESCHFA Spring meeting

Contact with patients' organisations through ad hoc initiative of HFA/ESC

Starting at month 24 contacts are established with patients organizations through ad hoc initiatives of the Heart Failure Association of the European Society of Cardiology every 2 years

Functional website

A public website for the trial is implemented and functional

Publicaciones

Overexpression of endothelial β 3 ‐adrenergic receptor induces diastolic dysfunction in rats

Autores: Justine Dhot, Marine Ferron, Valentine Prat, Antoine Persello, David Roul, David Stévant, Damien Guijarro, Nicolas Piriou, Virginie Aillerie, Angélique Erraud, Gilles Toumaniantz, Morteza Erfanian, Angela Tesse, Amandine Grabherr, Laurent Tesson, Séverine Menoret, Ignacio Anegon, Jean‐Noël Trochu, Marja Steenman, Michel De Waard, Bertrand Rozec, Benjamin Lauzier, Chantal Gauthier
Publicado en: ESC Heart Failure, Edición 7/6, 2020, Página(s) 4159-4171, ISSN 2055-5822
Editor: ESC Heat failure
DOI: 10.1002/ehf2.13040

Early nebivolol treatment is beneficial in myocardial infarction in rats partly through β3‐adrenoceptor remodelling

Autores: Leslie Audigane, Antoine Persello, Nicolas Piriou, Marine Ferron, Jean‐Noël Trochu, Benjamin Lauzier, Chantal Gauthier, Bertrand Rozec
Publicado en: Clinical and Experimental Pharmacology and Physiology, Edición 48/7, 2021, Página(s) 1007-1015, ISSN 0305-1870
Editor: Blackwell Publishing Inc.
DOI: 10.1111/1440-1681.13447

Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP‐activated protein kinase and autophagy

Autores: Emilie Dubois‐Deruy, Roselle Gelinas, Christophe Beauloye, Hrag Esfahani, Lauriane Y.M. Michel, Chantal Dessy, Luc Bertrand, Jean‐Luc Balligand
Publicado en: ESC Heart Failure, Edición 7/3, 2020, Página(s) 920-932, ISSN 2055-5822
Editor: ESC heart failure
DOI: 10.1002/ehf2.12648

Phosphatase regulatory subunits in beta-adrenergic signalling: a delicate balancing act

Autores: Jean-Luc Balligand
Publicado en: Cardiovascular Research, Edición 115/3, 2018, Página(s) 477-478, ISSN 0008-6363
Editor: Elsevier BV
DOI: 10.1093/cvr/cvy275

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Be

Autores: Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, Oana Brosteanu, Dirk Hasenclever, Barbara Casadei, Frank Edelmann, Gerasimos Filippatos, Damien Gruson, Ignatios Ikonomidis, Renaud Lhommel, Masliza Mahmod, Stefan Neubauer, Alexandre Persu, Bernhard L. Gerber, Stefan Piechnik, Burkert Pieske, Elisabeth Pieske-Kraigher, Fausto Pinto, Piotr Ponikowski, Michele Senni, Jean-Noël Trochu, Nancy Van Ov
Publicado en: ESC Heart Failure, 2018, ISSN 2055-5822
Editor: ESC Heart Failure
DOI: 10.1002/ehf2.12306

β3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes

Autores: Sophie Schobesberger, Peter T Wright, Claire Poulet, Jose L Sanchez Alonso Mardones, Catherine Mansfield, Andreas Friebe, Sian E Harding, Jean-Luc Balligand, Viacheslav O Nikolaev, Julia Gorelik
Publicado en: eLife, Edición 9, 2020, ISSN 2050-084X
Editor: eLife Sciences Publications
DOI: 10.7554/elife.52221

Seminar: Leçon publique sur l'HFpEF

Autores: Anne-Catherine Pouleur
Publicado en: 2015
Editor: Anne-Catherine Pouleur

Youtube video

Autores: Nancy Van Overstraeten
Publicado en: 2015
Editor: Youtube

seminar

Autores: Jean-Luc Balligand
Publicado en: 2015
Editor: ESC

Vers un nouveau traitement de l'insuffisance cardiaque ?

Autores: Jean-Luc Balligand
Publicado en: 2015
Editor: UCL

Towards a new treatment for cardiac remodeling ?

Autores: Nancy Van Overstraeten
Publicado en: 2015
Editor: UCL IREC

A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease

Autores: EU
Publicado en: 2015
Editor: EU

Une molécule pour soulager le coeur

Autores: Frédéric Soumois
Publicado en: Le Soir, Edición daily, 2015
Editor: Le Soir

Piechnik Group: Myocardial functional T1 mapping – Advanced cardiac magnetic resonance imaging techniques

Autores: S. Piechnik
Publicado en: 2018
Editor: Radcliffe Department of Medicine

On-going EU Projects

Autores: ESC
Publicado en: 2016
Editor: ESC

New and Emerging Therapies and Targets: Beta-3 Agonists

Autores: Lauriane Y. M. Michel, Jean-Luc Balligand
Publicado en: 2016, Página(s) 205-223
Editor: Springer International Publishing
DOI: 10.1007/164_2016_88

Buscando datos de OpenAIRE...

Resultado final

Publicaciones

Compartir esta página

Descargar